Oral administration is the preferred route of administration based on the convenience for and
compliance of the patient. Oral nanomedicines have been developed to overcome the …

Liver diseases have consistently posed substantial challenges to global health. It is crucial
to find innovative methods to effectively prevent and treat these diseases. In recent times …

Background Fibroblast growth factor 21 (FGF21) analogues have emerged as promising
therapeutic targets for non‐alcoholic steatohepatitis (NASH). However, the effects and safety …

Non‐alcoholic fatty liver disease (NAFLD) is a prominent cause of various chronic metabolic
hepatic diseases with limited therapeutics. Rubicon, an essential regulator in lysosomal …

Aims The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing annually,
leading to substantial medical and health burdens. Numerous studies have demonstrated …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent
chronic liver disease that can progress to end-stage conditions with life-threatening …

Introduction Non-alcoholic fatty liver disease (NAFLD) is a common liver disease
characterized by an increase in fat in liver cells. The outbreak of NAFLD is estimated to be …

Introduction Non-alcoholic fatty liver disease (NAFLD) is a common liver disease
characterized by an increase in fat in liver cells. The outbreak of NAFLD is estimated to be …

Nonalcoholic fatty liver disease (NAFLD) poses a significant global health burden,
necessitating precise diagnostic tools and effective treatment strategies. Peroxynitrite …